Company Overview - WuXi AppTec, established on December 1, 2000, is located in Shanghai and Hong Kong, and was listed on May 8, 2018. The company provides a comprehensive platform for the discovery, development, and manufacturing of small molecule chemical drugs, serving global pharmaceutical companies [1][2]. Financial Performance - For the first half of 2025, WuXi AppTec reported revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, reflecting a significant year-on-year growth of 101.92% [2]. - The company has distributed a total of 13.027 billion yuan in dividends since its A-share listing, with 9.373 billion yuan distributed over the past three years [3]. Stock Performance - As of August 29, WuXi AppTec's stock price increased by 81.74% year-to-date, with a 3.84% rise over the last five trading days, 4.96% over the last 20 days, and 52.52% over the last 60 days [1]. - The stock was trading at 97.61 yuan per share, with a market capitalization of approximately 288.097 billion yuan [1]. Shareholder Structure - As of June 30, 2025, WuXi AppTec had 235,500 shareholders, with the Hong Kong Central Clearing and Settlement System being the second-largest shareholder, holding 302 million shares, an increase of 56.0239 million shares from the previous period [3].

Market Performance - The pharmaceutical sector experienced a decline of -2.73% on August 27, 2025, underperforming the CSI 300 index by 1.24 percentage points, ranking 26th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, medical devices (-1.37%), medical research outsourcing (-1.98%), and blood products (-2.06%) performed relatively better, while in vitro diagnostics (-3.98%), vaccines (-3.45%), and hospitals (-3.12%) lagged behind [1] - Top three gainers included Nanjing New Pharmaceutical (+20.00%), Ailis (+17.00%), and Aomei Medical (+10.04%), while the largest decliners were Yuekang Pharmaceutical (-16.82%), Rejing Bio (-10.47%), and Guangshengtang (-10.32%) [1] Industry News - Gilead announced that the European Commission has approved its HIV-1 capsid inhibitor Yeytuo (Lenacapavir) for market release as a pre-exposure prophylaxis (PrEP) therapy, aimed at reducing the risk of HIV-1 infection in high-risk adults and adolescents (weighing at least 35 kg) [2] - Lenacapavir is a "first-in-class" long-acting HIV capsid inhibitor that interferes with the assembly and disassembly of the HIV capsid protein, demonstrating a 100% prevention rate of HIV infection in a study with 2,134 participants receiving biannual subcutaneous injections, outperforming the daily oral Truvada treatment group [2] Company News - Xingqi Eye Pharmaceutical (300573) reported a revenue of 1.163 billion yuan for the first half of 2025, a year-on-year increase of 30.38%, with a net profit attributable to shareholders of 335 million yuan, up 97.75% [3] - Nossger (301333) achieved a revenue of 380 million yuan in the first half of 2025, a slight increase of 0.18%, with a net profit of 61 million yuan, growing by 4.45% [3] - Mindray Medical (300706) reported a revenue of 16.743 billion yuan for the first half of 2025, a decline of 18.45%, with a net profit of 5.069 billion yuan, down 32.96% [3] - Zhongsheng Pharmaceutical (002317) announced that its subsidiary Zhongsheng Ruichuang has completed the first participant enrollment and dosing for two Phase III clinical trials (SHINING-2 and SHINING-3) of its innovative polypeptide drug RAY1225 injection [3]

Group 1 - The core viewpoint of the article is that Viatris (01873.HK) reported a decline in revenue for the first half of 2025, while net profit showed a slight increase due to strategic optimizations in its business structure [1] Group 2 - For the first half of 2025, the company's revenue was RMB 831.9 million, representing a year-on-year decrease of 15.27% [1] - The net profit for the same period was RMB 148.6 million, which is a year-on-year increase of 3.05% [1] - The basic earnings per share were RMB 0.06 [1] - The increase in net profit and adjusted non-IFRS net profit was primarily due to the continuous positive growth in the CRO business and strategic optimization of the Langhua business structure, which enhanced profitability [1]

异动分析 来源：新浪证券-红岸工作室 8月28日，金凯生科跌1.21%，成交额2.25亿元，换手率9.93%，总市值48.30亿元。 CRO概念+减肥药+阿尔茨海默概念+氟化工概念+人民币贬值受益 1、公司的主营业务是为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定 制研发生产服务。公司的主要产品是含氟类CDMO业务、非含氟类CDMO业务。 2、2023年8月8日互动易回复：公司上市的募投项目"医药中间体项目"和"年产 190 吨高端医药产品项目 包含司美格鲁肽（Semaglutide）口服制剂小分子吸收增强剂 SNAC 的中间体。 3、2023年9月21日互动易回复：公司为欧美生物创新药公司提供阿尔茨海默相关中间体服务。 4、2025年7月9日互动易，公司现有氟化生产能力包括特殊氟化剂氟化（如四氟化硫、氟化氢吡啶、氟 化氢三乙胺）、氟化氢氟化、氟化钾氟化等。 5、根据2024年年报，公司海外营收占比为61.18%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-1215.01万，占比0.05%，行业排名25 ...

Group 1 - A-shares opened lower with the Shanghai Composite Index down 0.1% and the ChiNext Index down 0.58%, with sectors like rare earth permanent magnets, energy metals, liquid cooling services, and insurance leading the declines [1] - Galaxy Securities forecasts increased market volatility, suggesting that technology growth will remain the mainstream, while military and non-ferrous sectors may see rotational rebounds [1] - The market is expected to enter an acceleration phase, with a recommendation to focus on relatively low-positioned sectors and quality stocks to wait for rotation and rebound opportunities [1] Group 2 - China Merchants Securities indicates that the market is currently in the second phase of a bull market, characterized by capital-driven dynamics and a focus on key sectors, recommending attention to innovative drugs, CXO, domestic computing power, robotics, and domestic AI agents [2] - The mid-year report performance disclosure is nearing completion, with high median growth rates observed in non-bank, agriculture, non-ferrous metals, steel, electronics, and machinery sectors for the first half of the year [2] - Analysts have recently upgraded profit forecasts for various sectors, including cross-border e-commerce, communication network equipment, LED, lithium battery equipment, medical R&D outsourcing, fluorochemical, gaming, film and animation production, and wind power components for 2025 [2] Group 3 - Orient Securities suggests that the market is facing a short-term adjustment but does not expect a major wave of correction, with strong support in the 3700-3750 point range [3] - The market is anticipated to undergo wide fluctuations to complete a "gear shift," returning to a "slow bull" atmosphere, with new highs still possible [3] - In the "slow bull" market, there is a focus on non-bank sectors and continued optimism for technology growth sectors, particularly AI computing, aerospace and military, and AI applications [3]

据证券之星公开数据整理，近期百诚医药（301096）发布2025年中报。截至本报告期末，公司营业总收 入3.32亿元，同比下降36.7%，归母净利润309.82万元，同比下降97.69%。按单季度数据看，第二季度 营业总收入2.04亿元，同比下降34.18%，第二季度归母净利润2929.58万元，同比下降65.29%。本报告 期百诚医药三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达58.28%。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率50.73%，同比减26.21%，净利率0.93%， 同比减96.35%，销售费用、管理费用、财务费用总计6722.32万元，三费占营收比20.23%，同比增 58.28%，每股净资产23.64元，同比减8.04%，每股经营性现金流-1.05元，同比减20.24%，每股收益0.03 元，同比减97.58% 分析师工具显示：证券研究员普遍预期2025年业绩在1785.0万元，每股收益均值在0.16元。 | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | ...

来源：新浪证券-红岸工作室 8月27日，药明康德跌1.45%，成交额60.37亿元，换手率2.50%，总市值2827.05亿元。 异动分析 CRO概念+创新药+人民币贬值受益 1、公司是国际领先的开放式能力与技术平台,为全球生物医药行业提供全方位、一体化的新药研发和生 产服务。 2、国内医药外包行业龙头,是国内最早开始从事医药研发生产外包的CRO和CMO一体化公司,高层管理 团队共拥有超过200项的已授权和申请中的专利成果;其主营业务为小分子化学药的发现、研发及生产的 全方位、一体化平台服务,以全产业链平台的形式面向全球制药企业提供各类新药的研发、生产及配套 服务;公司还在境外提供医疗器械检测及境外精准医疗研发生产服务。 3、根据2024年年报，公司海外营收占比为78.67%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-4.41亿，占比0.07%，行业排名51/51，连续2日被主力资金减仓；所属行业主力净流 入-15.97亿，连续2日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-4.41亿-8.81亿-11 ...

公司点评 | 博腾股份 营收利润同比增长，盈利能力提升 博腾股份（300363.SZ）2025 年中报点评 业绩概述：2025 年上半年公司实现营业收入 16.21 亿元（+19.88%），收入 增长主要来自小分子原料药业务，以及基因细胞治疗和新分子业务等两大新 业务板块；归母净利润 0.27 亿元（+115.91%），扣非归母净 0.06 亿元 （+103.69%），利润实现扭亏为盈主要因为收入提升带来的规模效应公司毛 利率提升，降本增效费用合计同比下降约 10%。 毛利率环比提升，新分子业务亏损影响减弱。2025 年上半年，公司整体毛 利率约 28%，同比提升约 9 个百分点，其中，第二季度毛利率环比第一季度 提升近 3 个百分点，达到约 29%。按市场区域分，海外市场毛利率约 40%； 国内市场毛利率为-3%，国内市场毛利率为负主要受市场竞争及基因细胞治 疗、小分子制剂、新分子等新业务亏损影响。剔除新业务影响后，国内市场 毛利率约为 14%，公司整体毛利率约 37%。新兴业务 25H1 合计影响净利润 约-1.11 亿元（合计减亏约 1260 万元），小分子制剂/基因细胞治疗/新分子业 务亏损分别为 4 ...

来源：新浪证券-红岸工作室 8月26日，金凯生科跌2.63%，成交额3.01亿元，换手率12.27%，总市值51.37亿元。 异动分析 CRO概念+减肥药+阿尔茨海默概念+氟化工概念+人民币贬值受益 1、公司的主营业务是为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定 制研发生产服务。公司的主要产品是含氟类CDMO业务、非含氟类CDMO业务。 2、2023年8月8日互动易回复：公司上市的募投项目"医药中间体项目"和"年产 190 吨高端医药产品项目 包含司美格鲁肽（Semaglutide）口服制剂小分子吸收增强剂 SNAC 的中间体。 3、2023年9月21日互动易回复：公司为欧美生物创新药公司提供阿尔茨海默相关中间体服务。 4、2025年7月9日互动易，公司现有氟化生产能力包括特殊氟化剂氟化（如四氟化硫、氟化氢吡啶、氟 化氢三乙胺）、氟化氢氟化、氟化钾氟化等。 5、根据2024年年报，公司海外营收占比为61.18%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资料显示，金凯(辽宁)生命科技股份有限公司位于辽宁省阜新市阜蒙县伊吗图 ...

Core Viewpoint - Tiger Med's stock price has shown fluctuations, with a year-to-date increase of 23.82% and a recent decline over the past 20 days, indicating mixed market sentiment towards the company [1][2]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is based in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1]. - The main business segments include clinical trial services (49.91% of revenue), clinical trial technical services (48.13%), and other services (1.95%) [1]. Financial Performance - For the first quarter of 2025, Tiger Med reported a revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit attributable to shareholders of 165 million yuan, down 29.61% year-on-year [2]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Structure - As of March 31, 2025, Tiger Med had 53,800 shareholders, an increase of 1.95% from the previous period. The top shareholders include various mutual funds and ETFs, with notable changes in holdings among major institutional investors [3].